Therapeutics News and Research

RSS

Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, confirmed today the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene’s Abraxane, demonstrated superimposable paclitaxel PK profiles. The study was conducted in women with metastatic breast cancer.

9 Nov 2015

First comprehensive genomic and biologic study of top skin disease-causing microbes

An international team of scientists, led by researchers from A*STAR's Genome Institute of Singapore (GIS), Institute of Medical Biology (IMB), and Bioinformatics Institute (BII), and P&G, have completed the first comprehensive genomic and biologic study of all species of Malassezia, one of the top skin disease-causing microbes.

9 Nov 2015

Scientists discover small molecule that can block growth of BRCA-deficient cancer cells

Cancer cells with mutations in BRCA1 or BRCA2 genes, which serve a vital role in preserving the integrity of the genetic code, are key targets for cancer therapeutics. Yet, few agents can selectively eliminate cells deficient in BRCA, and none can do so without the risk of inducing drug resistance.

6 Nov 2015

UM SOM Dean E. Albert Reece to be honored with 2015 David E. Rogers Award

The Association of American Medical Colleges announced today that University of Maryland School of Medicine Dean E. Albert Reece, MD, PhD, MBA, will receive the 2015 David E. Rogers Award, which honors a medical school faculty member who has made major contributions to improving the health and health care of the American people. He will be presented the Award on November 8, 2015 at the AAMC's Annual Awards Event.

6 Nov 2015

UCSF scientists identify eye drop chemical that may reverse cataracts

A chemical that could potentially be used in eye drops to reverse cataracts, the leading cause of blindness, has been identified by a team of scientists from UC San Francisco (UCSF), the University of Michigan (U-M), and Washington University in St. Louis (WUSTL).

6 Nov 2015

Hutchison MediPharma begins sulfatinib Phase I trial in US

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012) in the United States.

6 Nov 2015

MD Anderson Cancer Center, CytomX to study probody-enabled CAR-NK cell therapies

CytomX Therapeutics, a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today entered into a collaboration with The University of Texas MD Anderson Cancer Center to research Probody-enabled chimeric antigen receptor natural killer (CAR-NK) cell therapies, to be known as ProCAR-NK cell therapies.

6 Nov 2015

Researchers discover potential solution for side effects of immunotherapy treatment for Alzheimer's

It is estimated that 46.8 million people worldwide are living with dementia, with Alzheimer's disease the most common form.

5 Nov 2015

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.

5 Nov 2015

Janssen doses first patient in daratumumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that Janssen Biotech, Inc. has dosed the first patient in a clinical trial evaluating subcutaneous (SC) delivery of daratumumab with Halozyme's proprietary ENHANZE technology in multiple myeloma.

5 Nov 2015

UTA developing SMART bandage system that can monitor, cure wounds in real time

The University of Texas at Arlington is developing a sensing and therapeutic tool that will help doctors and other healthcare workers better monitor and heal patients' complex wounds more quickly.

5 Nov 2015

Johnson & Johnson signs definitive agreement to purchase Novira Therapeutics

Johnson & Johnson today announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection.

4 Nov 2015

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).

3 Nov 2015

$Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture$

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.

3 Nov 2015

Loughborough researchers secure £545,000 to help tackle Antimicrobial Resistance

Researchers at Loughborough University have secured £545,000 to help tackle growing resistance to antibiotics.

3 Nov 2015

Salk scientists uncover enzyme responsible for suppressing deadly lung cancer

Scientists at the Salk Institute have uncovered a molecule whose mutation leads to the aggressive growth of a common and deadly type of lung cancer in humans.

3 Nov 2015

Study highlights importance of sex-specific differences in complex biological processes

New research published in the Journal of Leukocyte Biology shows that male and female mice respond differently to inflammation at the cellular level. Specifically, in male mice the spleen acts as a source of white blood cells, while in females this is not the case. This discovery suggests that human studies are necessary to determine if current medical practices, which treat men and women generally the same, should be altered to reflect sex-specific differences.

3 Nov 2015

UAB study aims to provide improved care related to reproductive health of women with CF

For University of Alabama at Birmingham School of Nursing Assistant Professor Sigrid Ladores, Ph.D., investigating reproductive health concerns in adolescents and young adults with chronic illnesses, particularly those with cystic fibrosis, is not just a profession, it is a passion.

3 Nov 2015

Blocking calcium-signaling pathway could inhibit Ebola virus and other sources of deadly infections

The Ebola virus acts fast. The course of infection, from exposure to recovery, or death, can take as little as two weeks. That may not leave enough time for the immune system to mount an effective response.

31 Oct 2015

First patient of U.S. phase 1 trial treated with Genticel’s GTL001 candidate for HPV 16/18 infections

Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the first patient of the U.S. phase 1 clinical trial has been vaccinated with GTL001, the company’s first-in-class therapeutic vaccine candidate against HPV 16/18 infections.

31 Oct 2015

Therapeutics News and Research

Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

First comprehensive genomic and biologic study of top skin disease-causing microbes

Scientists discover small molecule that can block growth of BRCA-deficient cancer cells

UM SOM Dean E. Albert Reece to be honored with 2015 David E. Rogers Award

UCSF scientists identify eye drop chemical that may reverse cataracts

Hutchison MediPharma begins sulfatinib Phase I trial in US

MD Anderson Cancer Center, CytomX to study probody-enabled CAR-NK cell therapies

Researchers discover potential solution for side effects of immunotherapy treatment for Alzheimer's

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

Janssen doses first patient in daratumumab clinical trial using Halozyme's ENHANZE technology

UTA developing SMART bandage system that can monitor, cure wounds in real time

Johnson & Johnson signs definitive agreement to purchase Novira Therapeutics

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Loughborough researchers secure £545,000 to help tackle Antimicrobial Resistance

Salk scientists uncover enzyme responsible for suppressing deadly lung cancer

Study highlights importance of sex-specific differences in complex biological processes

UAB study aims to provide improved care related to reproductive health of women with CF

Blocking calcium-signaling pathway could inhibit Ebola virus and other sources of deadly infections

First patient of U.S. phase 1 trial treated with Genticel’s GTL001 candidate for HPV 16/18 infections

Industry Focus eBook - Microbiome (1st edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News